1. At a Glance – This Is Not Just Another EPC Story
Most “engineering companies” sell steel, cement and PowerPoints.
Fabtech seems to be selling something far more valuable — regulatory compliance wrapped in cleanrooms, purified water, and biopharma infrastructure.
That distinction matters.
This is a company with:
- FY26 revenue at ₹411 crore, up from ₹327 crore.
- PAT at ₹38 crore.
- ₹900+ crore order book, over 2.2x annual revenue.
- Presence in 62 countries.
- Export-heavy model with 85.7% international revenues.
- Asset-light structure, yet surprisingly respectable 13.6% ROCE.
- Listed just months ago and already talking acquisitions.
And yet market cap sits near ₹783 crore, barely 1.9x sales.
That mismatch deserves attention.
Usually when markets assign low multiples, one of three things is happening:
- It is junk disguised as growth.
- It is lumpy and misunderstood.
- It is early.
Fabtech appears to be fighting for category 2 or maybe even 3.
Interesting part?
Management is not pitching itself as contractor. In the February concall, they practically rejected that label.
“We are not a conventional contractor.”
That line matters.
Contractors get low multiples.
Platforms get premium multiples.
Management is clearly trying to migrate investor perception from EPC to life-sciences infrastructure platform.
Whether they earn that re-rating is the story.
And there are clues.
Order intake:
- FY23: ₹289 crore
- FY24: ₹404 crore
- FY25: ₹476 crore
Projects delivered:
Proposal conversion:
That is not random.
That looks like scaling.
Question for readers:
Is this an underfollowed niche compounder…
Or just a glorified project business with fancy vocabulary?
That debate is where the money often gets made.
Dry observation:
Most companies use IPO money to buy office chairs.
Fabtech wants to buy manufacturers in India, UAE, KSA and Egypt.
Slightly different ambition.
2. Introduction – Why This Story Is Strange
Normally SMEs coming to mainboard arrive with:
- stretched balance sheets
- promoter pledges
- aggressive narratives
- suspicious receivables
Fabtech has receivable issues (182 debtor days — not small).
But the rest?
Cleaner than expected.
Promoter holding:
68.94%
No pledges.
Debt/equity:
0.17
Cash jumped:
₹35 crore to ₹208 crore after IPO.
That changes survival math.
Now the more interesting bit.
They operate where countries want pharmaceutical self-sufficiency.
Africa.
Middle East.
GCC.
Not saturated markets.
Emerging demand creation markets.
That is different from fighting for share in a mature market.
And management is riding that theme aggressively.
Saudi vaccine facilities.
North African EU-GMP veterinary plant.
West Africa OSD project.
This is not random order flow.
This is thematic positioning.
Now add this:
Order book moved from ₹762 crore FY25 to ₹900 crore+ now.
That is growth even after execution.
Usually you want to see order books replenish.
They are.
Important nuance:
Q3 softness worried investors.
Management blamed shipment-led revenue recognition.
And Q4 appears to have validated that explanation.
Management walked the talk here.
That matters a lot.
Old concall promise:
Q4 catch-up.
Actual:
March quarter sales ₹159 crore versus ₹63 crore previous quarter.
Talk matched walk.
Rare species.
Can they keep doing it?
Different question.
3. Business Model – What Do They Even Do?
Imagine building a pharma factory.
You need:
- Cleanrooms
- HVAC
- Water systems
- Process equipment
- Validation
- Regulatory compliance
- Installation
Usually multiple vendors.
Fabtech says:
Give it to us.
That is the model.
Turnkey contributes:
75.5%
Standalone:
24.5%
Higher-value integrated business dominates.
This matters because turnkey can deepen relationships.
Also increase ticket sizes.
Management said average orders moved from US$1.5–5m historically to ~US$7m.
That is scale-up.
Asset-light model is clever.
They outsource manufacturing.
Keep engineering and execution control.
Less capex.
More scalability.
But…
Here comes auditor mode:
Asset-light can also mean vendor dependence.
And management itself wants acquisitions partly to reduce that risk.
So even they know the weak point.
Another thing I like:
They sit in a nasty niche.
Complex enough to deter competition.
Large enough
